Abstract
원핵생물체의 생명유지에 중요한 역할을 담당하는 유전자들을 밝히기 위해 미생물 유전체들 사이의 공통적 유전자를 파악하는 COG 알고리즘을 이용하였다. 원핵생물 711종 모두에 보존적인 것은 COG0080 (Ribosomal protein L11) 1개였다. 708종 이상의 원핵생물에 보존적인 22개의 ortholog 중 전사관련 2개, tRNA synthetase 관련4개, ribosamal large subunit 8개, ribosomal small subunit 7개였다. 700종 이상의 원핵생물에 보존적인 COG는 58개였다. 이중 리보좀을 구성하는 소단위체 등 번역 관련 COG가 50개(86.2%), 전사관련 COG가 4개(6.9%)로 나타나 생명현상에서의 단백질의 중요성을 알 수 있었다. 58개의 COG 중 보존성은 COG0060 (Isoleucyl tRNA synthetase)이 가장 높았고 COG0143 (Methionyl tRNA synthetase)이 가장 낮았다. 문(phylum)과 강(class) 수준에서 보존적 유전자들의 평균과 분산으로 유전체 분석을 수행한 결과 변이가 큰 고세균은 진정세균과 구분되었으며 편차는 일부 진정세균이 고세균보다 컸다. 보존적 유전자를 탐색하는 본 연구의 기법은 기초과학 연구와 함께 항균제 개발과 항암요법 개발 등에도 유용할 것이다. A COG (Cluster of Orthologous Groups of proteins) algorithm was applied to detect conserved genes in 711 prokaryotes. Only COG0080 (ribosomal protein L11) was common among all the 711 prokaryotes analyzed and 58 COGs were common in more than 700 prokaryotes. Nine COGs among 58, including COG0197 (endonuclease III) and COG0088 (ribosomal protein L4), were conserved in a form of one gene per one organism. COG0008 represented 1356 genes in 709 of the prokaryotes and this was the highest number of genes among 58 COGs. Twenty-two COGs were conserved in more than 708 prokaryotes. Of these, two were transcription related, four were tRNA synthetases, eight were large ribosomal subunits, seven were small ribosomal subunits, and one was translation elongation factor. Among 58 conserved COGs in more than 700 prokaryotes, 50 (86.2%) were translation related, and four (6.9%) were transcription related, pointing to the importance of protein-synthesis in prokaryotes. Among these 58 COGs, the most conserved COG was COG0060 (isoleucyl tRNA synthetase), and the least conserved was COG0143 (methionyl tRNA synthetase). Archaea and eubacteria were discriminated in the genomic analysis by the average distance and variation in distance of common COGs. The identification of these conserved genes could be useful in basic and applied research, such as antibiotic development and cancer therapeutics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.